Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background
NCT ID: NCT00162292
Last Updated: 2010-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
33 participants
INTERVENTIONAL
2005-11-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PoC in Rheumatoid Arthritis With Methotrexate
NCT00605735
Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis
NCT02638948
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
NCT01404585
Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
NCT00292422
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
NCT00458861
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-582949 and Methotrexate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of RA for ≥6 months
* Swollen or tender joint or ESR \>ULN. Subject must be on stable doses of MTX
* Women of Childbearing Potential
Exclusion Criteria
* CK\>ULN
* Cannot have taken Orencia or Remicade within 8 weeks of baseline, Humira or Enbrel within 4 weeks of baseline
* Use of H2 blockers or Proton Pump inhibitors while on study
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Desert Medical Advances
Palm Desert, California, United States
Boling Clinical Trials
Upland, California, United States
Delray Research Associates
Delray Beach, Florida, United States
Ocala Rheumatology Research Center
Ocala, Florida, United States
Phase Iii Clinical Research
Fall River, Massachusetts, United States
Covance Clinical Research Unit Inc.
Dallas, Texas, United States
Radiant Research San Antonio Northeast
San Antonio, Texas, United States
Healthcare Discoveries, Inc
San Antonio, Texas, United States
Local Institution
León, Guanajuato, Mexico
Local Institution
Metepec, State of Mexico, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM119-010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.